<DOC>
	<DOCNO>NCT00430625</DOCNO>
	<brief_summary>Gaucher disease rare lysosomal storage disorder cause deficiency enzyme glucocerebrosidase ( GCB ) . Due deficiency functional GCB , glucocerebroside accumulates within macrophage lead cellular engorgement , organomegaly , organ system dysfunction . The purpose study evaluate efficacy every week dose Gene-Activated® Human Glucocerebrosidase ( GA-GCB , velaglucerase alfa ) dose 45 60 U/kg treatment-naïve patient type 1 Gaucher disease .</brief_summary>
	<brief_title>A Study Gene-Activated® Human Glucocerebrosidase ( GA-GCB ) Enzyme Replacement Therapy Gaucher Disease</brief_title>
	<detailed_description>Type 1 Gaucher disease , common form , account 90 % case involve Central Nervous System ( CNS ) . Typical manifestation type 1 Gaucher disease include hepatomegaly , splenomegaly , thrombocytopenia , bleed tendency , anemia , hypermetabolism , skeletal pathology , growth retardation , pulmonary disease , decrease quality life . Gene-Activated® human glucocerebrosidase ( GA-GCB ; velaglucerase alfa ) produce continuous human cell line use proprietary gene-activation technology identical amino acid sequence naturally occur human enzyme . Velaglucerase alfa contain terminal mannose residue target enzyme macrophages-the primary target cell Gaucher disease . This study design determine efficacy , safety pharmacokinetics GA-GCB men , woman , child Type 1 Gaucher disease . Each patient duration treatment 12 month .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>Patient document diagnosis type 1 Gaucher disease , determine deficient glucocerebrosidase ( GCB ) activity relative normal measure leukocyte genotype analysis willing able provide write informed consent prior initiate studyrelated procedure Patient least 2 year age Patient Gaucher diseaserelated anemia Patient least moderate splenomegaly Patient Gaucher diseaserelated thrombocytopenia Patient readily palpable enlarge liver Patient receive treatment Gaucher disease within 30 month prior study entry Female patient childbearing potential agree use medically acceptable method contraception . Male patient must agree use medically acceptable method birth control . Patient must sufficiently cooperative participate study judge Investigator . Includes : Patient type 2 3 Gaucher disease suspect type 3 Gaucher disease Patient antibodypositive imiglucerase screen experience anaphylactic reaction imiglucerase Patient receive treatment investigational drug device within 30 day prior study entry Patient Human immunodeficiency virus ( HIV ) positive Patient hepatitis positive Patient present iron , folic acid and/or vitamin B12 deficiency sustain anemia screen Patient , patient 's parent ( ) , patient 's legal guardian ( ) is/are unable understand nature , scope , possible consequence study Patient significant comorbidity ( y ) might affect study data confound study result Patient pregnant and/or lactate female Patient unable comply protocol unlikely complete study , determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>VPRIV®</keyword>
	<keyword>Enzyme Replacement Therapy</keyword>
	<keyword>Gaucher disease</keyword>
	<keyword>glucocerebrosidase</keyword>
	<keyword>beta-glucocerebrosidase</keyword>
	<keyword>Acid beta-glucocerebrosidase</keyword>
	<keyword>glucosylceramidase</keyword>
	<keyword>D-glucosyl-N-acylsphingosine glucohydrolase</keyword>
	<keyword>gene activation</keyword>
	<keyword>human</keyword>
</DOC>